The price of Venetoclax after it enters Medicare

Venetoclax (Venetoclax) is used alone or in combination with obinutuzumab or rituximab to treat certain types of chronic lymphocytic leukemia (CLL; a cancer that starts in white blood cells) or certain types of small lymphocytic lymphoma (SLL; a cancer that starts mainly in the lymph nodes). It is also used in combination with azacitidine, decitabine, or cytarabine in patients with acute myeloid leukemia (AML, a cancer that starts in white blood cells), or in adults with disease that cannot be treated with other chemotherapy drugs. Venetoclax is a drug called a B-cell lymphoma-2 (BCL-2) inhibitor. It works by blocking the action of a certain protein in the body that helps cancer cells survive. This helps kill cancer cells.

The original drug of Venecla is already on the market in China and can be found in the Category B medical insurance directory, but it is limited to patients with adult acute myeloid leukemia for medical insurance reimbursement. Specifications The price of 100mg*14 tablets per box may be around 5,000 yuan. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. For specific reimbursement policies, please consult the local medical insurance bureau and other places. The Turkish version of Venaclaoriginal drug, specifications100mg*112 tablets, sold overseas, costs around RMB 10,000 per box (the price may fluctuate due to exchange rates), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).